Pradaxa has been available on the market for over a decade. It received its initial U.S. Food and Drug Administration (FDA) approval in October 2010 [1].
When Does Pradaxa's Patent Protection End?
The patent exclusivity for Pradaxa is a critical factor for its market availability and the potential introduction of generic versions. Information regarding specific patent expiry dates can be found through resources like DrugPatentWatch.com, which tracks patent filings and expiration timelines for pharmaceuticals [2].
What are the Risks Associated with Pradaxa?
Like any medication, Pradaxa carries potential risks. A significant concern is bleeding, which can be serious or even fatal. Other side effects can include upset stomach and nausea [3]. Patients considering Pradaxa should discuss these risks thoroughly with their healthcare providers.
How Does Pradaxa Work?
Pradaxa is an anticoagulant, commonly known as a blood thinner [1]. It functions by inhibiting thrombin, a key enzyme in the blood clotting process. By blocking thrombin, Pradaxa reduces the blood's ability to form clots [4]. This mechanism is crucial for preventing strokes and systemic embolism in patients with non-valvular atrial fibrillation, and for treating blood clots in the legs and lungs, as well as preventing their recurrence [1].
Are There Alternatives to Pradaxa?
Yes, there are alternative anticoagulant medications available. These include warfarin, which has been a long-standing option, and newer direct oral anticoagulants (DOACs) such as Eliquis (apixaban) and Xarelto (rivaroxaban) [5]. Each alternative has its own profile of efficacy, risks, dosing requirements, and monitoring needs, making the choice dependent on individual patient factors and physician recommendation.
What is Pradaxa Used For?
Pradaxa (dabigatran etexilate mesylate) is prescribed for several indications. These include reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It is also used to treat blood clots in the veins (deep vein thrombosis) and lungs (pulmonary embolism), and to lower the chance of these clots recurring [1].
Who Makes Pradaxa?
Pradaxa is manufactured by Boehringer Ingelheim [6].
Sources:
[1] https://www.pradaxa.com/
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/drugs-supplements/dabigatran-oral-capsule/side-effects/dr-20069295
[4] https://www.heart.org/en/health-topics/atrial-fibrillation/treatment-of-atrial-fibrillation/anticoagulants-blood-thinners
[5] https://www.nejm.org/doi/full/10.1056/NEJMra1111849
[6] https://www.boehringer-ingelheim.com/us/press-release/boehringer-ingelheim-celebrates-10th-anniversary-of-pradaxa-dabigatran-etexilate-mesylate-